In a significant advancement for cardiovascular medicine, medical technology firm Ventric Health has entered into a strategic partnership with pharmacy services provider Stellus Rx. The collaboration is designed to fundamentally alter the trajectory of heart failure (HF) management by linking rapid, point-of-care diagnostics with streamlined, pharmacist-led therapeutic interventions. By shifting the burden of care from overburdened specialist centers to the primary care environment, this initiative aims to accelerate the transition of patients from initial diagnosis to the implementation of four-pillar Guideline-Directed Medical Therapy (GDMT).
Main Facts: A Dual-Pronged Approach to Cardiovascular Health
The partnership addresses one of the most persistent bottlenecks in modern medicine: the "care gap" between identifying heart failure and achieving therapeutic optimization.
At the core of this initiative is Ventric Health’s Vivio system, an FDA-cleared diagnostic tool that allows primary care providers to assess left ventricular end-diastolic pressure in under five minutes. Unlike traditional echocardiograms, which often require referrals to cardiologists and lead to weeks of waiting, the Vivio system provides immediate data. It utilizes a combination of cardiac pressure and volume waveform analysis integrated with the digital Kansas City Cardiomyopathy Questionnaire (KCCQ-12) to detect Stage B and Stage C heart failure.
Crucially, the test is non-invasive and requires no imaging. When the system detects elevated pressure or early-stage disease, the patient is seamlessly referred to virtual clinical pharmacists at Stellus Rx. These pharmacists, embedded directly into the practice’s Electronic Health Record (EHR) system, assume the complex logistical and clinical tasks of medication management—tracking vitals, adjusting dosages, navigating insurance prior authorizations, and ensuring medication adherence through direct-to-home delivery.
Chronology: The Evolution of a Diagnostic-to-Therapeutic Pipeline
The journey to this partnership reflects the broader shift in the healthcare industry toward decentralized, value-based care.
- Pre-2025 (The Status Quo): Patients presenting with vague symptoms of fatigue or breathlessness in primary care settings faced a fragmented pathway. Referrals to cardiologists often resulted in delayed diagnoses, leading to the progression of heart failure and increased emergency department (ED) utilization.
- Early 2026: Ventric Health continued to refine its Vivio platform, gathering clinical evidence that point-of-care detection of hemodynamics could prevent the progression of asymptomatic Stage B heart failure.
- Late 2026 (The Strategic Pivot): Recognizing that diagnosis alone is insufficient without subsequent treatment, Ventric Health began evaluating the clinical and operational hurdles that prevent primary care physicians (PCPs) from prescribing the full spectrum of four-pillar GDMT.
- November 2026: Ventric Health and Stellus Rx formally announce their partnership, creating a closed-loop system where diagnosis immediately triggers a specialized pharmacological care plan. This integration marks a milestone in the effort to bring specialty-level heart failure management into the primary care office.
Supporting Data: The Challenge of GDMT Implementation
The clinical efficacy of the "four-pillar" approach to heart failure—comprising angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors—is well-documented. When administered correctly, these therapies significantly reduce mortality and hospital readmissions. However, the data reveals a stark reality regarding adoption.
Primary care providers often face significant operational friction when attempting to initiate these medications. The requirements for successful GDMT are rigorous:
- Frequent Laboratory Monitoring: Patients require regular blood work to track electrolytes and renal function as doses are titrated upward.
- Regular Adjustments: Optimizing the dosage of four different classes of drugs requires high-touch clinical oversight that many busy clinics cannot sustain.
- Insurance Hurdles: The complexity of prior authorizations for high-cost medications often leads to "prescription abandonment," where patients simply do not pick up their life-saving medication.
Without dedicated support, patients with comorbidities—such as chronic kidney disease, hypertension, or type 2 diabetes—are frequently maintained on sub-therapeutic doses. Studies suggest that even minor delays in reaching target doses of GDMT result in a statistically significant increase in hospitalizations and emergency visits. By outsourcing this titration and patient support to Stellus Rx, the partnership ensures that the patient reaches target doses as safely and quickly as possible.
Official Responses: Aligning Clinical Vision with Patient Outcomes
The leadership at Ventric Health views this collaboration as a fundamental transformation in how cardiovascular disease is conceptualized.
Thomas Cheek, Chief Medical Officer at Ventric Health, emphasized that the true value of medical technology lies in its ability to facilitate action. "Identifying heart failure early at the point of care is a critical first step, but the true value of diagnosis is only realised when it leads immediately to optimised, guideline-directed treatment," Cheek stated.
He further noted that the collaboration provides primary care providers with a "complete solution." By integrating the diagnostic speed of the Vivio system with the logistical and pharmacological expertise of Stellus Rx, the partnership removes the primary excuses for inertia in heart failure treatment. "We are enabling [providers] to detect elevated left ventricular end-diastolic pressure in minutes and quickly transition patients into a proven care management programme that drives long-term adherence and protects patient health," Cheek added.
Stellus Rx’s involvement brings a layer of operational robustness to the initiative. By embedding pharmacists into the EHR, the service ensures that the cardiologist’s expertise is mirrored in the primary care setting, effectively creating a "virtual specialty team" for every patient.
Implications: The Future of Value-Based Care
The implications of this partnership extend far beyond individual patient health. This model is specifically tailored for health systems, Medicare Accountable Care Organizations (ACOs), and Medicare Advantage plans—entities that are financially incentivized to keep patients out of the hospital.
Decentralization of Care
The traditional model of sending patients to tertiary care centers for heart failure management is becoming increasingly unsustainable. With an aging population and a rising incidence of chronic heart disease, the primary care clinic must become the hub of chronic disease management. This partnership proves that with the right technology and virtual support, general practitioners can manage complex cardiovascular cases without needing to refer the patient out of their practice.
Improving Adherence and Equity
The "compliance packaging" offered by Stellus Rx—where medications are sorted into daily doses and delivered to the home—addresses a massive, often overlooked barrier to adherence: the complexity of polypharmacy. For elderly patients or those with cognitive decline, managing four different classes of drugs can be overwhelming. By simplifying the delivery and administration of these drugs, the partnership mitigates the risk of non-compliance, which is a leading cause of preventable heart failure exacerbations.
Economic Impact
For Medicare ACOs, the value proposition is clear: reduce hospitalizations and ED visits by keeping patients within the primary care ecosystem. By automating the prior authorization process and managing the financial obstacles of drug access, the Ventric-Stellus model reduces the administrative burden on clinics while simultaneously lowering the total cost of care for the insurer.
A New Standard for Digital Health
This initiative serves as a blueprint for future digital health partnerships. It demonstrates that the most successful medical technology companies will be those that do not simply provide a diagnostic or a device, but those that provide a comprehensive, end-to-end clinical pathway. As the healthcare industry continues to move toward value-based payment models, the ability to demonstrate, track, and improve patient outcomes through such integrated workflows will become the new standard of care.
In conclusion, the partnership between Ventric Health and Stellus Rx represents a proactive approach to one of the most challenging conditions in medicine. By equipping primary care providers with the diagnostic tools to identify heart failure early and the pharmacist-led support to treat it aggressively, the collaboration aims to reduce the burden of heart disease, one patient at a time. The shift from reactive to proactive care is no longer just an ideal—it is becoming a technological and operational reality.
About the Author
